Casodex: preclinical studies.
Antiandrogens are effective drugs in the treatment of advanced prostatic cancer. The main problems associated with their use are their short half-lives, leading to fluctuating serum levels, and their non-selectivity, which leads to increases in serum LH and testosterone through centrally-mediated actions. Casodex is a pure, potent antiandrogen which, in pre-clinical studies, has been shown to have a long half-life and a high degree of peripheral selectivity. Casodex is as effective as surgical castration or medical castration with Zoladex in inhibiting the growth of a transplantable Dunning prostate tumor in rats. These properties suggest that Casodex, given once daily, would be an effective and well-tolerated monotherapy for advanced prostatic cancer.
Furr
B J
BJ
Bioscience 1, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.
D000813:Anilides / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D000818:Animals; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D006207:Half-Life; D008297:Male; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats; D014105:Tosyl Compounds
D000813:Anilides; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide